Open Access BASE2022

Celebrating 20 years of the UK Dermatology Clinical Trials Network: Part 1 – developing and delivering high quality independent clinical trials

Abstract

The UK Dermatology Clinical Trials Network (UK DCTN) formed in 2002 with the aim of developing and supporting high quality independent national clinical trials that address prioritised research questions for people with skin disease. Its philosophy is to democratise UK dermatological clinical research and to tackle important clinical questions that industry has no incentive to answer. The network also plays a key role in training and capacity development. Its membership of over 1,000 individuals includes dermatology consultants, trainees, dermatology nurses, general practitioners, methodologists and patients. Organisational structures are lean and include a co-ordinating team based at the Centre of Evidence-Based Dermatology, and an executive with independent members to ensure probity and business progression. A prioritisation panel and steering group enable a pipeline of projects to be prioritised and refined for external funding from independent sources. The UK DCTN has supported and completed 12 national clinical trials, attracting investment of over £15 million into UK clinical dermatology research. Trials have covered a range of interventions from drugs such as doxycycline (BLISTER), silk clothing for eczema (CLOTHES) or surgical interventions for hidradenitis suppurativa (THESEUS). Trials results are published in prestigious journals and have global impact. Genuine partnership with patients and carers has been a strong feature of the network since its inception. The UK DCTN is proud of its first 20 years of collaborative work and aims to remain at the forefront of independent dermatological health technology assessment as well as expanding into areas including diagnostics, AI, efficient studies and innovative designs.

Problem melden

Wenn Sie Probleme mit dem Zugriff auf einen gefundenen Titel haben, können Sie sich über dieses Formular gern an uns wenden. Schreiben Sie uns hierüber auch gern, wenn Ihnen Fehler in der Titelanzeige aufgefallen sind.